Table 3
Open in new tab

Outcome by TS expression level

DFSOS
n7‐yr DFS95% CIp valueHR95% CI7‐yr OS95% CIp valueHR95% CI
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by immunohistochemistry
High TS2030.63(0.56, 0.69)0.050.75(0.56, 1.01)0.70(0.63, 0.76).090.76(0.55, 1.01)
Low TS2600.54(0.47, 0.60)0.61(0.55, 0.67)
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by AQUA
Nuclear.0060.55(0.40, 0.76).300.67(0.47, 0.96)
≤6.051260.50(0.40, 0.58)0.63(0.54, 0.71)
>6.052900.67(0.61, 0.72)0.67(0.61, 0.72)
Cytoplasmic.010.58(0.42, 0.80).230.64(0.42, 0.97)
≤4.711170.50(0.40, 0.59)0.67(0.61, 0.72)
>4.712990.66(0.60, 0.71)0.76(0.67, 0.83)
Total.0090.57(0.41, 0.78).110.61(0.41, 0.89)
≤5.161230.51(0.41, 0.59)0.65(0.58, 0.71)
>5.162930.66(0.60, 0.71)0.76(0.69, 0.82)
Ratio.251.93(1.01, 3.66).231.93(1.01, 3.66)
≤1.04430.76(0.60, 0.86)0.87(0.72, 0.94)
>1.043730.60(0.55, 0.65)0.67(0.62, 0.72)
Patients not treated with 5‐FU, Study 9581: tumor TS expression by immunohistochemistry
High TS2680.76(0.70, 0.81).070.71(0.49, 1.04)0.81(0.75, 0.86).110.72(0.48, 1.08)
Low TS1670.69(0.61, 0.76)0.74(0.66, 0.80)
DFSOS
n7‐yr DFS95% CIp valueHR95% CI7‐yr OS95% CIp valueHR95% CI
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by immunohistochemistry
High TS2030.63(0.56, 0.69)0.050.75(0.56, 1.01)0.70(0.63, 0.76).090.76(0.55, 1.01)
Low TS2600.54(0.47, 0.60)0.61(0.55, 0.67)
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by AQUA
Nuclear.0060.55(0.40, 0.76).300.67(0.47, 0.96)
≤6.051260.50(0.40, 0.58)0.63(0.54, 0.71)
>6.052900.67(0.61, 0.72)0.67(0.61, 0.72)
Cytoplasmic.010.58(0.42, 0.80).230.64(0.42, 0.97)
≤4.711170.50(0.40, 0.59)0.67(0.61, 0.72)
>4.712990.66(0.60, 0.71)0.76(0.67, 0.83)
Total.0090.57(0.41, 0.78).110.61(0.41, 0.89)
≤5.161230.51(0.41, 0.59)0.65(0.58, 0.71)
>5.162930.66(0.60, 0.71)0.76(0.69, 0.82)
Ratio.251.93(1.01, 3.66).231.93(1.01, 3.66)
≤1.04430.76(0.60, 0.86)0.87(0.72, 0.94)
>1.043730.60(0.55, 0.65)0.67(0.62, 0.72)
Patients not treated with 5‐FU, Study 9581: tumor TS expression by immunohistochemistry
High TS2680.76(0.70, 0.81).070.71(0.49, 1.04)0.81(0.75, 0.86).110.72(0.48, 1.08)
Low TS1670.69(0.61, 0.76)0.74(0.66, 0.80)

aHigh TS 5 2+, 3+; low TS = 0,1+.

bLog‐rank p value.

cVariables except for the ratio are normalized by 1,000.

dExact Gauss method.

Abbreviations: AQUA, automated quantitative analysis; CI, confidence interval; DFS, disease‐free survival; 5‐FU, 5‐fluorouracil; HR, hazard ratio; OS, overall survival; TS, thymidylate synthase.

Table 3
Open in new tab

Outcome by TS expression level

DFSOS
n7‐yr DFS95% CIp valueHR95% CI7‐yr OS95% CIp valueHR95% CI
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by immunohistochemistry
High TS2030.63(0.56, 0.69)0.050.75(0.56, 1.01)0.70(0.63, 0.76).090.76(0.55, 1.01)
Low TS2600.54(0.47, 0.60)0.61(0.55, 0.67)
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by AQUA
Nuclear.0060.55(0.40, 0.76).300.67(0.47, 0.96)
≤6.051260.50(0.40, 0.58)0.63(0.54, 0.71)
>6.052900.67(0.61, 0.72)0.67(0.61, 0.72)
Cytoplasmic.010.58(0.42, 0.80).230.64(0.42, 0.97)
≤4.711170.50(0.40, 0.59)0.67(0.61, 0.72)
>4.712990.66(0.60, 0.71)0.76(0.67, 0.83)
Total.0090.57(0.41, 0.78).110.61(0.41, 0.89)
≤5.161230.51(0.41, 0.59)0.65(0.58, 0.71)
>5.162930.66(0.60, 0.71)0.76(0.69, 0.82)
Ratio.251.93(1.01, 3.66).231.93(1.01, 3.66)
≤1.04430.76(0.60, 0.86)0.87(0.72, 0.94)
>1.043730.60(0.55, 0.65)0.67(0.62, 0.72)
Patients not treated with 5‐FU, Study 9581: tumor TS expression by immunohistochemistry
High TS2680.76(0.70, 0.81).070.71(0.49, 1.04)0.81(0.75, 0.86).110.72(0.48, 1.08)
Low TS1670.69(0.61, 0.76)0.74(0.66, 0.80)
DFSOS
n7‐yr DFS95% CIp valueHR95% CI7‐yr OS95% CIp valueHR95% CI
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by immunohistochemistry
High TS2030.63(0.56, 0.69)0.050.75(0.56, 1.01)0.70(0.63, 0.76).090.76(0.55, 1.01)
Low TS2600.54(0.47, 0.60)0.61(0.55, 0.67)
Patients receiving 5‐FU‐based chemotherapy on Study C89803: tumor TS expression measured by AQUA
Nuclear.0060.55(0.40, 0.76).300.67(0.47, 0.96)
≤6.051260.50(0.40, 0.58)0.63(0.54, 0.71)
>6.052900.67(0.61, 0.72)0.67(0.61, 0.72)
Cytoplasmic.010.58(0.42, 0.80).230.64(0.42, 0.97)
≤4.711170.50(0.40, 0.59)0.67(0.61, 0.72)
>4.712990.66(0.60, 0.71)0.76(0.67, 0.83)
Total.0090.57(0.41, 0.78).110.61(0.41, 0.89)
≤5.161230.51(0.41, 0.59)0.65(0.58, 0.71)
>5.162930.66(0.60, 0.71)0.76(0.69, 0.82)
Ratio.251.93(1.01, 3.66).231.93(1.01, 3.66)
≤1.04430.76(0.60, 0.86)0.87(0.72, 0.94)
>1.043730.60(0.55, 0.65)0.67(0.62, 0.72)
Patients not treated with 5‐FU, Study 9581: tumor TS expression by immunohistochemistry
High TS2680.76(0.70, 0.81).070.71(0.49, 1.04)0.81(0.75, 0.86).110.72(0.48, 1.08)
Low TS1670.69(0.61, 0.76)0.74(0.66, 0.80)

aHigh TS 5 2+, 3+; low TS = 0,1+.

bLog‐rank p value.

cVariables except for the ratio are normalized by 1,000.

dExact Gauss method.

Abbreviations: AQUA, automated quantitative analysis; CI, confidence interval; DFS, disease‐free survival; 5‐FU, 5‐fluorouracil; HR, hazard ratio; OS, overall survival; TS, thymidylate synthase.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close